Artificial Intelligence ("AI") is poised to revolutionize the modern healthcare and life sciences industry, based on its potential to address unmet clinical demand, enhance risk analysis, improve diagnostics, and facilitate drug development processes. Healthcare and life sciences focused AI applications are projected to generate $150B in annual savings in the domestic healthcare economy by 2026. Many young companies are pioneering research and development in imaging, drug creation, and data collection, with over 70 launched in the last year. Given the dynamic nature of Artificial Intelligence technology and its universal applicability, this report seeks to provide a framework to understand the broader healthcare and life sciences AI landscape.
© In the U.S., America’s Growth Capital, LLC dba AGC Partners, member FINRA/SIPC. In Europe, America’s Growth Capital Europe, LLP (Appointed Representative Alternatives St. James, LLP which is authorized and regulated by the Financial Conduct Authority). America’s Growth Capital Europe, LLP is a Limited Liability Partnership incorporated in England and Wales (OC368580). Its registered address is 6th Floor, 9 Appold Street, London EC2A 2AP. The testimonials contained herein may not be representative of the experience of other customers or clients. Testimonials are no guarantee of future performance or success. Deals marked with an “*” are non-AGC deals.
